NL8801147A - Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit. - Google Patents

Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit. Download PDF

Info

Publication number: NL8801147A
Authority: NL; Netherlands
Prior art keywords: dna; probe; fragments; mini; separation
Prior art date: 1988-05-02

Application number

NL8801147A

Other languages

English (en)

Dutch (nl)

Original Assignee

Tno

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-02

Filing date

1988-05-02

Publication date

1989-12-01

1988-05-02 Application filed by Tno filed Critical Tno

1988-05-02 Priority to NL8801147A priority Critical patent/NL8801147A/nl

1989-04-28 Priority to AT89201095T priority patent/ATE95247T1/de

1989-04-28 Priority to EP89201095A priority patent/EP0349024B1/de

1989-04-28 Priority to ES89201095T priority patent/ES2044052T3/es

1989-04-28 Priority to DE89201095T priority patent/DE68909514T2/de

1989-05-01 Priority to JP1112758A priority patent/JPH078240B2/ja

1989-05-01 Priority to US07/345,887 priority patent/US5068176A/en

1989-12-01 Publication of NL8801147A publication Critical patent/NL8801147A/nl

Links

238000000034 method Methods 0.000 title claims abstract description 23
230000007614 genetic variation Effects 0.000 title claims description 9
239000000523 sample Substances 0.000 claims abstract description 58
238000000926 separation method Methods 0.000 claims abstract description 54
108091092919 Minisatellite Proteins 0.000 claims abstract description 44
239000012634 fragment Substances 0.000 claims abstract description 43
108020004414 DNA Proteins 0.000 claims description 64
238000004458 analytical method Methods 0.000 claims description 56
238000009396 hybridization Methods 0.000 claims description 28
108091008146 restriction endonucleases Proteins 0.000 claims description 16
238000012546 transfer Methods 0.000 claims description 14
229920002401 polyacrylamide Polymers 0.000 claims description 13
239000012528 membrane Substances 0.000 claims description 10
238000001962 electrophoresis Methods 0.000 claims description 8
239000004677 Nylon Substances 0.000 claims description 5
229920001778 nylon Polymers 0.000 claims description 5
102000053602 DNA Human genes 0.000 claims description 4
108020003215 DNA Probes Proteins 0.000 claims description 4
239000003298 DNA probe Substances 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
239000003398 denaturant Substances 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
108020004518 RNA Probes Proteins 0.000 claims description 2
239000003391 RNA probe Substances 0.000 claims description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims 1
230000002285 radioactive effect Effects 0.000 claims 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 12
238000001514 detection method Methods 0.000 abstract description 4
108091081062 Repeated sequence (DNA) Proteins 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 34
239000000499 gel Substances 0.000 description 33
201000010099 disease Diseases 0.000 description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
108700028369 Alleles Proteins 0.000 description 28
238000012360 testing method Methods 0.000 description 15
238000002105 Southern blotting Methods 0.000 description 13
238000002844 melting Methods 0.000 description 13
230000008018 melting Effects 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
230000002068 genetic effect Effects 0.000 description 10
239000003550 marker Substances 0.000 description 10
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
208000026350 Inborn Genetic disease Diseases 0.000 description 8
208000024556 Mendelian disease Diseases 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000000211 autoradiogram Methods 0.000 description 7
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 7
229960005542 ethidium bromide Drugs 0.000 description 7
230000008775 paternal effect Effects 0.000 description 7
201000011510 cancer Diseases 0.000 description 6
238000013507 mapping Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
208000028782 Hereditary disease Diseases 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000008774 maternal effect Effects 0.000 description 5
206010007269 Carcinogenicity Diseases 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000006399 behavior Effects 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
231100000260 carcinogenicity Toxicity 0.000 description 4
230000007670 carcinogenicity Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
102000052575 Proto-Oncogene Human genes 0.000 description 3
108700020978 Proto-Oncogene Proteins 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
238000010191 image analysis Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
102000054765 polymorphisms of proteins Human genes 0.000 description 3
239000000779 smoke Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
238000007399 DNA isolation Methods 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
238000009835 boiling Methods 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
231100000357 carcinogen Toxicity 0.000 description 2
231100000315 carcinogenic Toxicity 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004141 dimensional analysis Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000005204 segregation Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
ZRKLEAHGBNDKHM-HTQZYQBOSA-N (2r,3r)-2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide Chemical compound C=CCNC(=O)[C@H](O)[C@@H](O)C(=O)NCC=C ZRKLEAHGBNDKHM-HTQZYQBOSA-N 0.000 description 1
241000576133 Alphasatellites Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
238000010953 Ames test Methods 0.000 description 1
231100000039 Ames test Toxicity 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
108091029523 CpG island Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
238000003723 Smelting Methods 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000002669 amniocentesis Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000027455 binding Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000004042 decolorization Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
231100000722 genetic damage Toxicity 0.000 description 1
238000012254 genetic linkage analysis Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000010439 graphite Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000004519 grease Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000008520 organization Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000003793 prenatal diagnosis Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
108091035233 repetitive DNA sequence Proteins 0.000 description 1
102000053632 repetitive DNA sequence Human genes 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000017105 transposition Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NL8801147A 1988-05-02 1988-05-02 Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit. NL8801147A (nl)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
NL8801147A NL8801147A (nl)	1988-05-02	1988-05-02	Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.
AT89201095T ATE95247T1 (de)	1988-05-02	1989-04-28	Verfahren zur gleichzeitigen bestimmung von dns- sequenzvariationen von zahlreichen stellen und ein satz dafuer.
EP89201095A EP0349024B1 (de)	1988-05-02	1989-04-28	Verfahren zur gleichzeitigen Bestimmung von DNS-Sequenzvariationen von zahlreichen Stellen und ein Satz dafür
ES89201095T ES2044052T3 (es)	1988-05-02	1989-04-28	Un metodo para la determinacion simultanea de variaciones de secuencias de dna en un gran numero de sitios, y un estuche de materiales para dicho metodo.
DE89201095T DE68909514T2 (de)	1988-05-02	1989-04-28	Verfahren zur gleichzeitigen Bestimmung von DNS-Sequenzvariationen von zahlreichen Stellen und ein Satz dafür.
JP1112758A JPH078240B2 (ja)	1988-05-02	1989-05-01	遺伝的変異を検出する方法
US07/345,887 US5068176A (en)	1988-05-02	1989-05-01	Method for the simultaneous determination of dna sequence variations at a large number of sites, and a kit suitable therefor

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8801147A NL8801147A (nl)	1988-05-02	1988-05-02	Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.
NL8801147		1988-05-02

Publications (1)

Publication Number	Publication Date
NL8801147A true NL8801147A (nl)	1989-12-01

Family

ID=19852240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8801147A NL8801147A (nl)	1988-05-02	1988-05-02	Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.

Country Status (7)

Country	Link
US (1)	US5068176A (de)
EP (1)	EP0349024B1 (de)
JP (1)	JPH078240B2 (de)
AT (1)	ATE95247T1 (de)
DE (1)	DE68909514T2 (de)
ES (1)	ES2044052T3 (de)
NL (1)	NL8801147A (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9100132A (nl) *	1991-01-25	1992-08-17	Ingeny Bv	Werkwijze voor het detecteren van dna sequentievariatie.
WO1992013971A1 (en) *	1991-02-05	1992-08-20	Lifecodes Corporation	Molecular genetic identification using probes that recognize polymorphic loci
US5213669A (en) *	1992-01-31	1993-05-25	Beckman Instruments, Inc.	Capillary column containing a dynamically cross-linked composition and method of use
US5354442A (en) *	1992-05-21	1994-10-11	The United States Of America As Represented By The Secretary Of The Commerce	Matrix modification in the electrophoretic separation of nucleic acids
US5503980A (en) *	1992-11-06	1996-04-02	Trustees Of Boston University	Positional sequencing by hybridization
US5795714A (en) *	1992-11-06	1998-08-18	Trustees Of Boston University	Method for replicating an array of nucleic acid probes
US6436635B1 (en)	1992-11-06	2002-08-20	Boston University	Solid phase sequencing of double-stranded nucleic acids
US6007987A (en) *	1993-08-23	1999-12-28	The Trustees Of Boston University	Positional sequencing by hybridization
US5495432A (en) *	1994-01-03	1996-02-27	Industrial Technology Research Institute	Apparatus and method for sampling rate conversion
US5736025A (en) *	1994-04-04	1998-04-07	Genomyx Inc.	Control of temperature gradients during gel electrophoresis using turbulent gas flow
NL9401082A (nl) *	1994-06-28	1996-02-01	Ingeny Bv	Werkwijze voor het detecteren van mutaties.
US7803529B1 (en)	1995-04-11	2010-09-28	Sequenom, Inc.	Solid phase sequencing of biopolymers
CA2223061C (en) *	1995-06-06	2008-04-22	Jan Vijg	Method of and apparatus for diagnostic dna testing
US6048691A (en) *	1996-05-13	2000-04-11	Motorola, Inc.	Method and system for performing a binding assay
AU7019498A (en)	1997-04-10	1998-10-30	Diagnocure Inc.	Pca3, pca3 genes, and methods of use
ES2260059T3 (es)	1999-09-29	2006-11-01	Diagnocure Inc.	Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
DE60045932D1 (de)	2000-09-01	2011-06-16	Gen Probe Inc	HIV-1-Sequenzverstärkung zur Erkennung von Sequenzen in Zusammenhang mit Wirkstoffresistenz-Mutationen
EP1320745A4 (de) *	2000-09-01	2008-10-01	Applera Corp	System und verfahren zur temperaturgradienten-kapillarelektrophorese
AU2002214569A1 (en) *	2000-10-11	2002-04-22	Spectrumedix Corporation	System and method for determining the presence of methylated cytosines in polynucleotides
EP1202211A3 (de) *	2000-10-26	2004-12-22	Riken	Computerprogramm zur Analyse von genomischer DNS
WO2003033743A1 (en) *	2001-10-18	2003-04-24	Spectrumedix Corporation	System and method for temperature gradient capillary electrophoresis
US6872530B2 (en) *	2002-04-24	2005-03-29	Spectrumedix, Llc	Method for determining the presence of DNA variants using peptide nucleic acid probes
AU2003256579A1 (en) *	2002-07-16	2004-02-02	Spectrumedix Llc	Method and system for comparative genomics for organisms using temperature gradient electrophoresis
AU2004209578A1 (en)	2003-02-07	2004-08-19	Diagnocure Inc.	Method to detect prostate cancer in a sample
US7303879B2 (en) *	2003-07-31	2007-12-04	Applera Corporation	Determination of SNP allelic frequencies using temperature gradient electrophoresis
ATE498682T1 (de) *	2004-09-02	2011-03-15	Lifeind Ehf	Zweidimensionale strangform- und längenabhängige trennung von nukleinsäurefragmenten
DE102004048334A1 (de) *	2004-10-01	2006-04-06	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verbessertes elektrophoretisches Trennverfahren für die Analyse der Genexpression
CA2491067A1 (en)	2004-12-24	2006-06-24	Stichting Katholieke Universiteit	Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006122401A1 (en) *	2005-05-16	2006-11-23	Institut De Recherches Cliniques De Montreal/I.R.C.M.	Negative regulation of nk cell functions by eat-2, a sap-related adaptor expressed in innate immune cells
WO2007056394A2 (en) *	2005-11-08	2007-05-18	The Trustees Of Columbia University In The City Of New York	Genetic markers of true low birth weight
JP5716217B2 (ja) *	2009-12-15	2015-05-13	公益財団法人ヒューマンサイエンス振興財団	長鎖繰返し配列を含有する遺伝子又は遺伝子産物の選択又は優先的回収方法
WO2014140167A1 (en)	2013-03-14	2014-09-18	Dsm Ip Assets B.V.	Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
WO2014140165A1 (en)	2013-03-14	2014-09-18	Dsm Ip Assets B.V.	Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3503978A1 (de) *	1984-08-01	1986-02-06	Detlev Prof.Dr. 4000 Düsseldorf Riesner	Verfahren zur frueherkennung von pflanzenkrankheiten
EP0219842A1 (de) *	1985-10-23	1987-04-29	Allied Corporation	Nukleinsäuretest mittels Segmentpaarhemmung oder -konkurrenz

1988
- 1988-05-02 NL NL8801147A patent/NL8801147A/nl not_active Application Discontinuation
1989
- 1989-04-28 EP EP89201095A patent/EP0349024B1/de not_active Expired - Lifetime
- 1989-04-28 DE DE89201095T patent/DE68909514T2/de not_active Expired - Fee Related
- 1989-04-28 ES ES89201095T patent/ES2044052T3/es not_active Expired - Lifetime
- 1989-04-28 AT AT89201095T patent/ATE95247T1/de not_active IP Right Cessation
- 1989-05-01 US US07/345,887 patent/US5068176A/en not_active Expired - Fee Related
- 1989-05-01 JP JP1112758A patent/JPH078240B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0349024A1 (de)	1990-01-03
DE68909514D1 (de)	1993-11-04
EP0349024B1 (de)	1993-09-29
ES2044052T3 (es)	1994-01-01
ATE95247T1 (de)	1993-10-15
US5068176A (en)	1991-11-26
JPH078240B2 (ja)	1995-02-01
JPH02104299A (ja)	1990-04-17
DE68909514T2 (de)	1994-01-20

Legal Events

Date	Code	Title	Description
1989-12-01	A1B	A search report has been drawn up
1991-01-02	BV	The patent application has lapsed

Publication	Publication Date	Title
US5068176A (en)	1991-11-26	Method for the simultaneous determination of dna sequence variations at a large number of sites, and a kit suitable therefor
Paternoster et al.	2002	A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization
Pinkel et al.	1986	Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes
Alsobrook II et al.	1997	The genetics of Tourette syndrome
US20020182628A1 (en)	2002-12-05	Multiple fusion probes
EP0553258A1 (de)	1993-08-04	Identifizierung und bestimmung der vaterschaft durch detektion der anwesenheit oder abwesenheit von mehreren nukleotidsäure sequenzien
Gicquel et al.	1998	Assessment of Turner’s syndrome by molecular analysis of the X chromosome in growth-retarded girls
Morris et al.	1999	Two years' prospective experience using fluorescence in situ hybridization on uncultured amniotic fluid cells for rapid prenatal diagnosis of common chromosomal aneuploidies
NL9100132A (nl)	1992-08-17	Werkwijze voor het detecteren van dna sequentievariatie.
Morgan et al.	1990	The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia
DE10147232A1 (de)	2002-07-11	PCR-Reaktionsgemisch für Fluoreszenz-basierende Genexpressions- und Genmutationsanalysen
Kanmogne et al.	1997	Wide variation in DNA content among isolates of Trypanosoma brucei ssp.
Cawood	1989	DNA fingerprinting.
DE60025871T2 (de)	2006-10-05	Genetisches Screening Verfahren und Vorrichtung
Cui et al.	2022	FISH—in Routine Diagnostic Settings
EP1798291B1 (de)	2011-05-18	Verfahren für die Detektion von Mutationen in Nukleinsaüren, und die Anwendung in der Diagnose von genetischen Krankheiten und Krebs
Visvardis et al.	2000	Diversity of peripheral blood mononuclear cells as revealed by a novel multiple microgel “comet assay”
Wetzel et al.	2000	Use of fluorescence genomic in situ hybridization (GISH) to detect the presence of alien chromatin in wheat lines differing in nuclear DNA content
Amari et al.	1986	Comparison of histones in normal and xeroderma pigmentosum lymphoblastoid cells
Uitterlinden	1995	Gene and genome scanning by two‐dimensional DNA typing
Berg et al.	2012	Genetic approaches to coronary heart disease and hypertension
Reining et al.	1994	Detection of trisomy 12 in chronic lymphocytic leukaemia: comparison of a polymerase chain reaction based technique with fluorescence in situ hybridization
Tucker	2004	Radiation cytogenetics: from chromosomes to single nucleotides and from metaphase cells to tissues
Petibone et al.	2018	Fluorescence in situ hybridization in genotoxicity testing
NL1010012C2 (nl)	2000-03-07	Werkwijze voor het detecteren van nucleotidensequenties en/of nucleotide-bindende eiwitten.